These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19066329)

  • 21. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ; Bruce Lyons A; Fraser CK; Hayball JD; Hughes TP
    Blood; 2008 Apr; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract]   [Full Text] [Related]  

  • 22. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
    Verstovsek S; Tefferi A; Cortes J; O'Brien S; Garcia-Manero G; Pardanani A; Akin C; Faderl S; Manshouri T; Thomas D; Kantarjian H
    Clin Cancer Res; 2008 Jun; 14(12):3906-15. PubMed ID: 18559612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
    Bryant G
    Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKT cell-infiltrating aseptic meningitis on the central nervous system in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib.
    Imataki O; Arai T; Yamaoka G; Matsuoka A; Uemura M
    Ann Hematol; 2014 Nov; 93(11):1935-6. PubMed ID: 24756695
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
    Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
    Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
    Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical management of dasatinib for maximum patient benefit.
    Galinsky I; Buchanan S
    Clin J Oncol Nurs; 2009 Jun; 13(3):329-35. PubMed ID: 19502192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The longitudinal analysis of large granular lymphocytosis in patients with Philadelphia chromosome-positive leukemia treated with dasatinib.
    Shimura Y; Horiike S; Tsutsumi Y; Hatsuse M; Okano A; Fuchida S; Kobayashi T; Matsumoto Y; Kuroda J; Kawata-Iida E; Uchiyama H; Uoshima N; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    Int J Hematol; 2015 Oct; 102(4):426-33. PubMed ID: 26267232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy.
    Bassan R; Rambaldi A; Allavena P; Abbate M; Marini B; Barbui T
    Am J Hematol; 1988 Oct; 29(2):85-93. PubMed ID: 3263796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
    Ishiyama KI; Kitawaki T; Otsuka Y; Takaori-Kondo A; Kadowaki N
    Cancer Sci; 2021 Feb; 112(2):523-536. PubMed ID: 33064914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
    Chang H; Hung YS; Chou WC
    Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.